中华肝脏外科手术学电子杂志
中華肝髒外科手術學電子雜誌
중화간장외과수술학전자잡지
CHINESE JOURNAL OF HEPATIC SURGERY(ELECTRONIC EDITION)
2014年
3期
148-151
,共4页
易述红%易慧敏%傅斌生%牛斌%孟炜%李华%许赤%杨扬%陈规划
易述紅%易慧敏%傅斌生%牛斌%孟煒%李華%許赤%楊颺%陳規劃
역술홍%역혜민%부빈생%우빈%맹위%리화%허적%양양%진규화
肝移植%手术后并发症%肿瘤,继发原发性%危险因素%吸烟%免疫抑制剂
肝移植%手術後併髮癥%腫瘤,繼髮原髮性%危險因素%吸煙%免疫抑製劑
간이식%수술후병발증%종류,계발원발성%위험인소%흡연%면역억제제
Liver transplantation%Postoperative complications%Neoplasms,second primary%Risk factors%Smoking%Immunosuppressive agents
目的:探讨肝移植术后新发恶性肿瘤的危险因素和防治措施。方法回顾性研究2003年10月至2008年12月在中山大学附属第三医院肝移植中心行肝移植且接受完整随访的416例中9例新发恶性肿瘤患者临床资料。其中男7例,女2例;年龄30~60岁,中位年龄57岁。术前有吸烟史4例、长期二手烟接触史3例,1例有肝细胞癌(肝癌)家族史。所有患者均签署知情同意书,符合医学伦理学规定。肝移植手术方式均为同种异体改良背驮式肝移植术,采用甲泼尼龙+他克莫司(FK506)或环孢素(CsA)免疫抑制方案。患者术后接受随访,观察新发恶性肿瘤的发生、治疗、预后等情况。结果肝移植术后新发恶性肿瘤发生率为2.2%(9/416),其中消化系统恶性肿瘤3例、呼吸系统恶性肿瘤3例、血液系统恶性肿瘤2例、软组织肉瘤1例。肝移植至肿瘤确诊的时间为10~73个月,中位时间49个月。患者接受相应的手术治疗、放射治疗(放疗)、化学药物治疗(化疗)。5例术后免疫抑制剂转换为西罗莫司,4例FK506用量为肿瘤确诊前的半量。随访期间6例死亡,均死于肿瘤进展和多器官功能衰竭。确诊距死亡的时间为2~25个月,中位时间9个月。结论吸烟和免疫抑制剂的应用可能为肝移植术后新发恶性肿瘤发生的高危因素,进行规范化随访并针对高危因素早期防治是提高疗效的关键。
目的:探討肝移植術後新髮噁性腫瘤的危險因素和防治措施。方法迴顧性研究2003年10月至2008年12月在中山大學附屬第三醫院肝移植中心行肝移植且接受完整隨訪的416例中9例新髮噁性腫瘤患者臨床資料。其中男7例,女2例;年齡30~60歲,中位年齡57歲。術前有吸煙史4例、長期二手煙接觸史3例,1例有肝細胞癌(肝癌)傢族史。所有患者均籤署知情同意書,符閤醫學倫理學規定。肝移植手術方式均為同種異體改良揹馱式肝移植術,採用甲潑尼龍+他剋莫司(FK506)或環孢素(CsA)免疫抑製方案。患者術後接受隨訪,觀察新髮噁性腫瘤的髮生、治療、預後等情況。結果肝移植術後新髮噁性腫瘤髮生率為2.2%(9/416),其中消化繫統噁性腫瘤3例、呼吸繫統噁性腫瘤3例、血液繫統噁性腫瘤2例、軟組織肉瘤1例。肝移植至腫瘤確診的時間為10~73箇月,中位時間49箇月。患者接受相應的手術治療、放射治療(放療)、化學藥物治療(化療)。5例術後免疫抑製劑轉換為西囉莫司,4例FK506用量為腫瘤確診前的半量。隨訪期間6例死亡,均死于腫瘤進展和多器官功能衰竭。確診距死亡的時間為2~25箇月,中位時間9箇月。結論吸煙和免疫抑製劑的應用可能為肝移植術後新髮噁性腫瘤髮生的高危因素,進行規範化隨訪併針對高危因素早期防治是提高療效的關鍵。
목적:탐토간이식술후신발악성종류적위험인소화방치조시。방법회고성연구2003년10월지2008년12월재중산대학부속제삼의원간이식중심행간이식차접수완정수방적416례중9례신발악성종류환자림상자료。기중남7례,녀2례;년령30~60세,중위년령57세。술전유흡연사4례、장기이수연접촉사3례,1례유간세포암(간암)가족사。소유환자균첨서지정동의서,부합의학윤리학규정。간이식수술방식균위동충이체개량배타식간이식술,채용갑발니룡+타극막사(FK506)혹배포소(CsA)면역억제방안。환자술후접수수방,관찰신발악성종류적발생、치료、예후등정황。결과간이식술후신발악성종류발생솔위2.2%(9/416),기중소화계통악성종류3례、호흡계통악성종류3례、혈액계통악성종류2례、연조직육류1례。간이식지종류학진적시간위10~73개월,중위시간49개월。환자접수상응적수술치료、방사치료(방료)、화학약물치료(화료)。5례술후면역억제제전환위서라막사,4례FK506용량위종류학진전적반량。수방기간6례사망,균사우종류진전화다기관공능쇠갈。학진거사망적시간위2~25개월,중위시간9개월。결론흡연화면역억제제적응용가능위간이식술후신발악성종류발생적고위인소,진행규범화수방병침대고위인소조기방치시제고료효적관건。
Objective To investigate the risk factors, prophylaxis and treatment of de novo malignancies following liver transplantation (LT). Methods Clinical data of 9 patients with de novo malignancies out of 416 patients who underwent LT and received complete follow-up in Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University from October 2003 to December 2008 were analyzed retrospectively. Seven patients were male and 2 were female. The age ranged from 30 to 60 years old with a median of 57 years old. Four cases had smoking history before operation, 3 cases had long-term passive smoke exposure, and 1 case had family history of hepatocellular carcinoma. The informed consents of all patients were obtained and the ethical committee approval was received. Allogeneic modified piggyback LT was performed in all the patients. The immunosuppressive regimen was methylprednisolone + tacrolimus (FK506) or cyclosporine A (CsA). The patients were followed up after operation and the incidence, treatments and prognosis of malignancies were observed. Results The incidence of malignancies following LT was 2.2% (9/416) including digestive system malignancies (n=3), respiratory system malignancies (n=3), hematological malignancies (n=2) and soft tissue sarcoma (n=1). The elapsed time from LT to diagnosis was 10 to 73 months (median:49 months). The patients received surgery, radiotherapy, chemotherapy accordingly. After the operation, the immunosuppressant of 5 patients changed to sirolimus and 4 patients continued to take FK506 half the dose before tumor diagnosis. Six cases died of tumor progress and multiple organ failure during the follow-up. The interval time from diagnosis of tumor to death ranged from 2 to 25 months (median: 9 months). Conclusions Smoking and use of immunosuppressant may be high risk factors of malignancy following liver transplantation. Normative follow-up and prophylaxis and treatment at the earlier stage are the keys to improve the therapeutic effect.